Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3
1(33.3%)
N/A
1(33.3%)
Phase 2
1(33.3%)
3Total
Phase 3(1)
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06007235Not ApplicableRecruiting

CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa

Role: collaborator

NCT02973893Phase 2Unknown

Study of VF001-DP in Patients With Chronic Venous Leg Ulcers

Role: collaborator

NCT01421966Phase 3Completed

Evaluation of CureXcell® in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes

Role: collaborator

All 3 trials loaded